Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Garrett

Showing results (341-350 of 352) with videos related to

Pageof 36
Sort By:
Clinical Pharmacology and Therapeutics|June 7, 2012
UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human studyY-H Wang, M Trucksis, J J McElwee, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Journal of the National Cancer Institute|September 5, 2012
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomasArthur P Chou, Reshmi Chowdhury, Sichen Li, et al.
Annals of the New York Academy of Sciences|January 31, 2023
Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia reportJennifer Cable, Siddharth Balachandran, Lisa P Daley-Bauer, et al.
Biorxiv : the Preprint Server for Biology|November 25, 2020
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Science (New York, N.Y.)|January 26, 2021
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibodyC Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Mbio|October 5, 2021
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape MutantsDenise Haslwanter, M Eugenia Dieterle, Anna Z Wec, et al.
Science Translational Medicine|June 14, 2023
Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibodyEva Mittler, Alexandra Serris, Emma S Esterman, et al.
Biorxiv : the Preprint Server for Biology|June 27, 2020
Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic AnalysisNatalia G Herrera, Nicholas C Morano, Alev Celikgil, et al.
ACS Omega|January 18, 2021
Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic AnalysisNatalia G Herrera, Nicholas C Morano, Alev Celikgil, et al.
Pageof 36

Showing results (341-350 of 352) with videos related to

Sort By:
Pageof 36
Clinical Pharmacology and Therapeutics|June 7, 2012
UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human studyY-H Wang, M Trucksis, J J McElwee, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Journal of the National Cancer Institute|September 5, 2012
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomasArthur P Chou, Reshmi Chowdhury, Sichen Li, et al.
Annals of the New York Academy of Sciences|January 31, 2023
Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia reportJennifer Cable, Siddharth Balachandran, Lisa P Daley-Bauer, et al.
Biorxiv : the Preprint Server for Biology|November 25, 2020
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Science (New York, N.Y.)|January 26, 2021
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibodyC Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Mbio|October 5, 2021
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape MutantsDenise Haslwanter, M Eugenia Dieterle, Anna Z Wec, et al.
Science Translational Medicine|June 14, 2023
Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibodyEva Mittler, Alexandra Serris, Emma S Esterman, et al.
Biorxiv : the Preprint Server for Biology|June 27, 2020
Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic AnalysisNatalia G Herrera, Nicholas C Morano, Alev Celikgil, et al.
ACS Omega|January 18, 2021
Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic AnalysisNatalia G Herrera, Nicholas C Morano, Alev Celikgil, et al.
Pageof 36